PRACTECAL-EE: Economic Evaluation of New MDR TB Regimens

Sponsor

Medecins Sans Frontieres, Netherlands (Other)

Overall Status

Recruiting

CT.gov ID

NCT04207112

Collaborator

London School of Hygiene and Tropical Medicine (Other), Ministry of Health, Republic of Uzbekistan (Other), Ministry of Public Health, Republic of Belarus (Other), THINK TB & HIV Investigative Network (Other), University of Liverpool (Other), Wits Health Consortium (Pty) Ltd (Other), LSHTM Clinical Research Department (Other)

200

Enrollment

Locations

Arms

21.3

Anticipated Duration (Months)

28.6

Patients Per Site

1.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The current treatment regimen for MDR-TB has poor outcomes and costs of treating MDR-TB are greater than treating drug susceptible TB, both in terms of health service and patient-incurred costs. Urgent action is needed to Identify short, effective and tolerable treatments for people with MDR-TB. The PRACTECAL economic evaluation sub-study (PRACTECAL-EE) will take place alongside the TB PRACTECAL trial, aiming to assess the costs to patients and providers of such regimens and to estimate the cost-effectiveness and poverty impact of an introduction of new MDR-TB regimens in the three countries participating in the main study.

Condition or Disease	Intervention/Treatment	Phase
Multi-drug Resistant Tuberculosis Extensively Drug-Resistant Tuberculosis Pulmonary Tuberculoses	Drug: Bedaquiline Drug: Pretomanid Drug: Moxifloxacin Drug: Linezolid Drug: Clofazimine Drug: Standard Drugs	Phase 2/Phase 3

Detailed Description

Multidrug resistant tuberculosis (MDR TB), tuberculosis (TB) that does not respond to at least isoniazid and rifampicin, is currently a public health issue. The current treatment regimen for MDR-TB has poor outcomes and costs of treating MDR-TB are greater than treating drug susceptible TB, both in terms of health service and patient-incurred costs. (1, 2). Key changes to recommendations for MDR-TB treatment regimens were published recently by the World Health Organization after an assessment of new evidence(3). In this rapid communication, three main changes to the standard MDR regimen were recommended: firstly, the withdrawal of injectable antibiotics; secondly, the inclusion of bedaquiline in a recommended longer regimen (ie 20 months); and thirdly, the recommendation of use for a shorter regimen only for specific conditions. It also highlights the urgent need for evidence to inform better optimal treatment choices for MDR-TB patients. Economic evaluations of such bedaquiline-containing regimens will provide additional important information for decision makers who need to consider its economic value along with clinical efficacy when planning for introduction.

TB PRACTECAL is a randomised, controlled trial to evaluate the safety and efficacy of investigational regimens containing bedaquiline and pretomanid for the treatment of MDR-TB in adults. It has been designed in two stages: stage 1 is a phase II trial aiming to identify two regimens containing bedaquiline and pretomanid for further evaluation based on safety and efficacy outcomes after 8 weeks of treatment. Stage 2 is a phase III trial to evaluate the safety and efficacy of the two investigational regimens containing bedaquiline and pretomanid selected in stage 1 compared with the standard of care at 72 weeks post-randomisation (Clinical trial protocol, study number: NCT02589782). This economic evaluation sub-study (PRACTECAL EE) will take place alongside TB PRACTECAL aiming to assess the costs to patients and providers of such regimens and to estimate the cost-effectiveness and poverty impact of an introduction of new MDR-TB regimens in the three countries participating in the main study.

The decision problem is stated as the evaluation of the new treatment regimen for MDR TB patients to inform the GRADE process at a global level, and health technology assessments (HTA) in the trial host countries, as applied to regimens for drug-resistant TB. During these processes (both at global level, GRADE, and at country level, HTA), the review of economic evidence produced alongside clinical trials focuses around patient outcomes and then on resources needed to answer the question of whether a new regimen should be considered for introduction. Population level considerations can also be included, especially in a second stage where the decision problem has advanced from whether to recommend a new regimen, to how to introduce it to achieve maximum health at a limited budget.

The overall aim of this sub study is to estimate the probability that new MDR-TB regimens containing bedaquiline and pretomanid will be cost-effective from a societal as compared to the standard of care for MDR-TB patients in three settings: Uzbekistan, South Africa, and Belarus.

A secondary aim is to assess the costs from a provider perspective of treating patients with these new regimens (new MDR-TB regimens containing bedaquiline and pretomanid), and estimate the impact of new regimens on prevalence of catastrophic costs due to TB.

The specific objectives of this sub-study are, in each setting:

to assess the costs from a provider's perspective for selected facilities in the intervention and control arms;
to assess the costs from a patient's perspective for a sample of patients seeking care in study facilities in the intervention and control arms;
To estimate the prevalence of catastrophic costs in the intervention and control arms;
to assess the probability of new regimens being cost-effective at different willingness-to-pay thresholds from a societal perspective using a Markov model.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

200 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Health Services Research

Official Title:

Economic Evaluation of New MDR TB Regimens (PRACTECAL EE)

Actual Study Start Date :

Oct 20, 2020

Anticipated Primary Completion Date :

Jul 30, 2022

Anticipated Study Completion Date :

Jul 31, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Regimen 1: Bedaquiline, Pretomanid, Linezolid, Moxifloxacin Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Moxifloxacin: 400 mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated Drug: Bedaquiline Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.	Drug: Bedaquiline Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death. Other Names: Sirturo R207910 TMC207 Drug: Pretomanid Pretomanid is an nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria. Other Names: PA-824 Drug: Moxifloxacin Moxifloxacin is an 8-methoxyquinolone class antimicrobial that is a potent inhibitor of DNA gyrase and topoisomerase IV in bacteria Other Names: Avelox BAY 12-8039 Drug: Linezolid Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease. Other Names: Zyvox
Experimental: Regimen 2: Bedaquiline, Pretomanid, Linezolid, Clofazimine Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated Clofazimine: 50 mg (less than 33 kg), 100 mg (more than 33 kg) for 24 weeks	Drug: Bedaquiline Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death. Other Names: Sirturo R207910 TMC207 Drug: Pretomanid Pretomanid is an nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria. Other Names: PA-824 Drug: Linezolid Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease. Other Names: Zyvox Drug: Clofazimine Clofazimine (Cfz) is a lipophilic riminophenazine licensed for treatment of leprosy. Its mechanism(s) of action remains unclear, but existing evidence suggests production of reactive oxygen species within Mycobacterium tuberculosis is one mechanism. Other Names: Lamprene
Experimental: Regimen 3: Bedaquiline, Pretomanid, Linezolid Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated)	Drug: Bedaquiline Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death. Other Names: Sirturo R207910 TMC207 Drug: Pretomanid Pretomanid is an nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria. Other Names: PA-824 Drug: Linezolid Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease. Other Names: Zyvox
Active Comparator: Control regimen Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB	Drug: Standard Drugs Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.

Outcome Measures

Primary Outcome Measures

Incremental cost incurred per disability adjusted life year (DALY) averted: Societal Perspective [108 weeks post randomisation]
Incremental cost incurred per disability adjusted life year (DALY) averted with the intervention regimen compared to the standard of care from societal perspective. DALYs will be modelled up to a life time horizon using a markov model.
Incremental cost per disability adjusted life year (DALY) averted: Provider Perspective [108 weeks post randomisation]
Incremental cost per disability adjusted life year (DALY) averted with the intervention regimen compared to the standard of care from provider perspective. DALYs will be modelled up to a life time horizon using a markov model.

Secondary Outcome Measures

Mean cost per month of treatment [108 weeks post randomisation]
Mean cost per month of treatment for different regimens and type of patient (MDR-TB, pre-XDR-TB (resistant to fluoroquinolone) and XDR-TB)
Mean cost per course of treatment for different types of patients [108 weeks post randomisation]
Mean cost per course of treatment for different types of patients (MDR-TB, pre-XDR-TB (resistant to fluoroquinolone), XDR-TB) and by category (training, monitoring, service delivery and drugs)
Incremental total cost of intervention for the trial population [108 weeks post randomisation]
Incremental total cost of intervention for the trial population, over the trial duration
Incremental total cost of intervention for the modelling cohort [108 weeks post randomisation]
Incremental total cost of intervention for the modelling cohort, over a life time horizon

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

adults with Mycobacterium tuberculosis resistant to at least rifampicin by either molecular or phenotypic drug susceptibility test.

Exclusion Criteria:

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Republican Scientific and Practical Centre for Pulmonology and Tuberculosis hospital	Minsk		Belarus
2	Helen Joseph Hospital	Johannesburg	Gauteng	South Africa	2092
3	Doris Goodwin Hospital	Pietermaritzburg	KwaZulu Natal	South Africa
4	THINK Clinical Trial Unit, Hillcrest	Durban	KwaZulu-Natal	South Africa	3650
5	King DinuZulu Hospital	Durban	KwaZulu-Natal	South Africa	4091
6	Republican TB Hospital No. 2	Nukus	Karakalpakstan	Uzbekistan
7	Sh Alimov Republican Specialised Scientific-Practical Medical Centre for Phthysiology and Pulmonology Hospital	Tashkent		Uzbekistan